Key result
Preemptive injection of atropine did not reduce the occurrence of a >15% reduction in mean heart rate during percutaneous ethanol injection compared to placebo.
Why the study?
Does preemptive atropine prevent cardiac dysrhythmias in patients with hepatocellular carcinoma undergoing percutaneous ethanol instillation?
RCT (n=40)
Double-blind
1:1
Does preemptive atropine prevent cardiac dysrhythmias in patients with hepatocellular carcinoma undergoing percutaneous ethanol instillation?
Preemptive atropine injection does not prevent bradyarrhythmias during percutaneous ethanol injection for hepatocellular carcinoma and should not be routinely recommended.
Answers are grounded in this paper and cite their sources.
Preemptive atropine should not be routinely recommended during percutaneous ethanol injection for HCC; challenges assumptions of prophylactic benefit.
INTRODUCTION: Percutaneous ethanol injection (PEI) is an established method in the treatment of hepatocellular carcinoma (HCC). During this procedure, severe cardiac bradyarrhythmias can occur. A preemptive injection of atropine is recommended by professional guidelines to prevent these dysrhythmias. METHODS: Patients scheduled for PEI were randomized 1:1 to receive 0.5 mg atropinehydrochloride or placebo in a double-blind randomized placebo-controlled trial. Patients were electrocardiogram monitored, which were then analysed by an experienced rhythmologist blinded to the treatment arm. RESULTS: Patients in 40 consecutive PEI sessions were included. During PEI, a significant reduction in the mean heart rate (>15%) was seen in 15% of patients in the placebo group (median, -37%; range, 15-41%) and in 25% of patients receiving atropine (median, -20%; range, 16-64%). There was no significant difference between both groups. During PEI, two patients (10%) in the placebo group developed a sinuatrial block (SAB). Four patients in the atropine group (20%) developed arrhythmias: three patients SAB, one of them with escape rhythm and one AV-bundle block. Blood ethanol levels post-PEI, amount of instilled ethanol, tumour size and location were not different between patients with or without dysrhythmias. CONCLUSION: In this randomized-controlled trial, a preprocedure atropine injection did not prevent the occurrence of bradyarrhythmias. Prophylactic use of atropine might not be effective and therefore cannot be recommended as a routine procedure. Clinicaltrials.gov-identifier: NCT00575523.
No takes yet. Share an insight, caveat, or question.
Arnulf et al. (2009) conducted an RCT in Hepatocellular carcinoma (n=40). Atropine vs. Placebo was evaluated on Significant reduction in mean heart rate (>15%). Preemptive injection of atropine did not reduce the occurrence of a >15% reduction in mean heart rate during percutaneous ethanol injection compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: